6-chloro-2-(4-ethoxyphenylamino)-3-nitropyridine | 1097099-52-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-chloro-2-(4-ethoxyphenylamino)-3-nitropyridine
• 英文别名: 6-chloro-N-(4-ethoxyphenyl)-3-nitropyridin-2-amine
• CAS: 1097099-52-9
• 化学式: C₁₃H₁₂ClN₃O₃
• 分子量: 293.71
• InChiKey: ADFMRBBIGRMCHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 对乙氧基苯胺 在 碳酸氢钠 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以86%的产率得到6-chloro-2-(4-ethoxyphenylamino)-3-nitropyridine
  参考文献：
  名称：

  Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents

  摘要：

  Based on a shared structural core of diarylamine in several known anticancer drugs as well as a new cytotoxic hit 6-chloro-2-(4-cyanophenyl)amino-3-nitropyridine (7), 30 diarylamines and diarylethers were designed, synthesized, and evaluated for cytotoxic activity against A549, KB, KB-vin, and DU145 human tumor cell lines (HTCL). Four new leads 11e, 12, 13a, and 13b were discovered with GI(50) values ranging from 0.33 to 3.45 mu M. Preliminary SAR results revealed that a diarylamine or diarylether could serve as an active structural core, meta-chloro and ortho-nitro groups on the A-ring (either pyridine or phenyl ring) were necessary and crucial for cytotoxic activity, and the para-substituents on the other phenyl ring (B-ring) were related to inhibitory selectivity for different tumor cells. In an investigation of potential biological targets of the new leads, high thoughput kinase screening discovered that new leads 11e, 12 and 13b especially inhibit Mer tyrosine kinase, a proto-oncogene associated with munerous tumor types, with IC50 values of 2.2-3.0 mu M. Therefore, these findings provide a good starting point to optimize a new class of compounds as potential anticancer agents, particularly targeting Mer tyrosine kinase. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.014

文献信息

• 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PREPARATION METHODS AND USES THEREOF
  申请人：Xie Lan

  公开号：US20120053213A1

  公开（公告）日：2012-03-01

  The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.

  这项发明涉及作为非核苷类HIV逆转录酶抑制剂的2-(4-取代苯胺基)多取代吡啶化合物，以及其制备方法和用途。具体而言，该发明涉及具有式I或其药学上可接受的盐的化合物，其中R1、R2、R3、R4、R5、R6、R7和X如描述中所定义。该发明的式I化合物是一种具有新骨架结构的抗HIV活性化合物。
• THE 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS THE INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PRAPARATION METHODS AND USES THEREOF
  申请人：Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

  公开号：EP2351739A1

  公开（公告）日：2011-08-03

  The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.

  本发明涉及作为非核苷类HIV逆转录酶抑制剂的2-(4-取代苯基氨基)多取代吡啶化合物及其制备方法和用途。具体而言，本发明涉及式 I 的化合物或其药学上可接受的盐类，其中 R1、R2、R3、R4、R5、R6、R7 和 X 如描述中所定义。本发明的式 I 化合物是一种具有新型骨架结构的抗 HIV 活性化合物。
• 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS THE INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PRAPARATION METHODS AND USES THEREOF
  申请人：Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

  公开号：EP2351739B1

  公开（公告）日：2013-07-31
• US8933106B2
  申请人：——

  公开号：US8933106B2

  公开（公告）日：2015-01-13
• Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents
  作者：Xiao-Feng Wang、Xing-Tao Tian、Emika Ohkoshi、Bingjie Qin、Yi-Nan Liu、Pei-Chi Wu、Mann-Jen Hour、Hsin-Yi Hung、Keduo Qian、Rong Huang、Kenneth F. Bastow、William P. Janzen、Jian Jin、Susan L. Morris-Natschke、Kuo-Hsiung Lee、Lan Xie

  DOI：10.1016/j.bmcl.2012.08.014

  日期：2012.10

  Based on a shared structural core of diarylamine in several known anticancer drugs as well as a new cytotoxic hit 6-chloro-2-(4-cyanophenyl)amino-3-nitropyridine (7), 30 diarylamines and diarylethers were designed, synthesized, and evaluated for cytotoxic activity against A549, KB, KB-vin, and DU145 human tumor cell lines (HTCL). Four new leads 11e, 12, 13a, and 13b were discovered with GI(50) values ranging from 0.33 to 3.45 mu M. Preliminary SAR results revealed that a diarylamine or diarylether could serve as an active structural core, meta-chloro and ortho-nitro groups on the A-ring (either pyridine or phenyl ring) were necessary and crucial for cytotoxic activity, and the para-substituents on the other phenyl ring (B-ring) were related to inhibitory selectivity for different tumor cells. In an investigation of potential biological targets of the new leads, high thoughput kinase screening discovered that new leads 11e, 12 and 13b especially inhibit Mer tyrosine kinase, a proto-oncogene associated with munerous tumor types, with IC50 values of 2.2-3.0 mu M. Therefore, these findings provide a good starting point to optimize a new class of compounds as potential anticancer agents, particularly targeting Mer tyrosine kinase. (C) 2012 Elsevier Ltd. All rights reserved.